Vasopressin antagonists in acute heart failure syndromes

Cesare Orlandi, Filippo Brandimarte, Mihai Gheorghiade

Research output: Chapter in Book/Report/Conference proceedingChapter


The contribution of neurohormonal abnormalities in the pathophysiology of chronic heart failure (CHF) is well established. Attenuation of the excessive and continuous activation of angiotensin II and β-adrenergic receptors in patients with CHF with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, respectively, has resulted in substantial reductions in morbidity and mortality. However, it is not clear whether intervention with other neuroendocrine modulators (e.g., tumor necrosis factor [TNF] or endothelin) could result in similar benefits.

Original languageEnglish (US)
Title of host publicationAcute Heart Failure
PublisherSpringer London
Number of pages5
ISBN (Print)9781846287817
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Vasopressin antagonists in acute heart failure syndromes'. Together they form a unique fingerprint.

Cite this